Abstract
To compare safety and efficacy of pregabalin and desvenlafaxine respectively for treating Neuropathic Pain. 04 patients were entered into a prospective observational study of pregabalin and desvenlafaxine in neuropathic pain for 6 months. Patients were randomly arranged into 2 groups, 52 patients received pregabalin and other group of 52 patients received desvenlafaxine. The initialassessement were made during the first visit and two subsequent reviews were done in 2 months interval, up to 6 months. Visual analogue pain scores, incidence of side effects were measured. The pain scores(mean±S.D.) were 5.37±1.14 and 6.7±1.39 respectively for desvenlafaxine and pregabalin.The low pain score of desvenlafaxine was associated with prolonged pain relief. There were pronounced differences in incidence of side effect between the two drugs: pregabalin, 36.5% compared to desvenlafaxine, 7%. The study findings revealed that desvenlafaxine is more safe and efficacious than pregabalin. Thus this study recommends the use of desvenlafaxine for neuropathic pain over pregabalin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Innovative Science and Research Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
